Not all people with CLL demand therapy. In spite of all current advances, the iwCLL still recommends watchful observation for sufferers with asymptomatic illness.86 This advice is based on not less than two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 Both equally trials https://raymondi318fmu6.blogdiloz.com/profile